Title

Screening of NCI-DTP Library to Identify New Drug Candidates for Borrelia burgdorferi

Document Type

Article

Language

eng

Publication Date

3-2017

Publisher

Nature Publishing Group (Macmillan Publishers Limited)

Source Publication

Journal of Antibiotics

Source ISSN

0021-8820

Abstract

Lyme disease is the most rapidly growing tick borne zoonotic disease of the Northern Hemisphere and is among the 10 most commonly reported nationally notifiable diseases in the United States.1 Clinical presentations include erythema migrans, fever, chills, muscle and joint pain.2, 3 Though these symptoms tend to fade away even without therapeutic intervention, a significant number of untreated patients develop arthritis and persistent myalgia following exposure to Borrelia burgdorferi.4 Furthermore, 10–20% of patients treated for Lyme disease develop symptoms considered typical, or even exaggerated, including muscle, joint pain and generalized fatigue5, 6. This condition is referred as post-treatment lyme disease syndrome (PTLDS).

Comments

Journal of Antibiotics, Vol. 70, (March 2017): 308-312. DOI.